Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial
Autore:
Berman, RM; Anand, A; Cappiello, A; Miller, HL; Hu, XS; Oren, DA; Charney, DS;
Indirizzi:
W Vet Affairs Med Ctr, Affect Disorders Program, W Haven, CT USA W Vet Affairs Med Ctr W Haven CT USA Disorders Program, W Haven, CT USA W Vet Affairs Med Ctr, Dept Psychiat, W Haven, CT USA W Vet Affairs Med Ctr W Haven CT USA Ctr, Dept Psychiat, W Haven, CT USA Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA Yale Univ New Haven CT USA iv, Sch Med, Dept Psychiat, New Haven, CT USA
Titolo Testata:
BIOLOGICAL PSYCHIATRY
fascicolo: 9, volume: 45, anno: 1999,
pagine: 1170 - 1177
SICI:
0006-3223(19990501)45:9<1170:TUOPWF>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
AUTORECEPTOR BLOCKADE; ANTIDEPRESSANT DRUGS; RECEPTOR ACTIVATION; 5-HT1A RECEPTORS; MICRODIALYSIS; PAROXETINE; BRAIN; SEROTONIN(1A); PHARMACOLOGY; ANTAGONIST;
Keywords:
pindolol; fluoxetine; controlled trial; serotonin receptors;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
26
Recensione:
Indirizzi per estratti:
Indirizzo: Berman, RM Connecticutaven,al Hlth Ctr, Clin Neurosci Res Unit, 34 Pk St,Rm 360, New H Connecticut Mental Hlth Ctr 34 Pk St,Rm 360 New Haven CT USA 06519
Citazione:
R.M. Berman et al., "The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial", BIOL PSYCHI, 45(9), 1999, pp. 1170-1177

Abstract

Background: Preliminary reports have suggested that concomitant institution of pindolol and serotonin reuptake inhibitors robustly hastens clinical response; however, contradictory evidence from a randomized double-blind, controlled trial was recently reported by this group in a population of depressed patients who were prescribed fluxoetine and pindolol. Herein, we report final results from an extended sample size. Methods: Drug-free outpatients with a major depressive episode were randomized in a double-blind manner to one of two treatment conditions: fluoxetine (20 mg daily) with pindolol (7.5 to 10 mg daily) or fluoxetine (20 mg daily) with placebo. After 6 weeks, patients were followed for 3 more,weeks ina single-blind manner, on fluoxetine and placebo pindolol. Results: Eighty-six patients completed at least 1 or more weeks on protocol, with 45 and 41 patients randomized to the pindolol and placebo groups respectively. After 2 weeks on protocol, partial remission (i.e., at least 50% decrease in depression rating scores from baseline) rates for pindolol (16%) and placebo (19%) groups were comparable. By the study's end, a partialremission was achieved at least transiently for 67% of the pindolol group and 80% of the placebo group. Pindolol treatment was associated with statistically significant reduction in blood pressure and pulse as compared to the control group. The two groups did not have overall differences in rates of attrition, time to response, and side effects. Conclusions: In accord with our previously published findings, these extended results do nor support the efficacy of pindolol in hastening clinical response to fluoxetine in a patient population with predominantly chronic and recurrent depression. (C) 1999 Society of Biological Psychiatry.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 10:13:30